{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:45:06Z","timestamp":1785444306825,"version":"3.56.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1097\/md.0000000000001677","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T12:48:26Z","timestamp":1445690906000},"page":"e1677","source":"Crossref","is-referenced-by-count":87,"title":["Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens"],"prefix":"10.1097","volume":"94","author":[{"given":"P.G.","family":"Clay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-26-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-014-0024-z","article-title":"Single-tablet regimens in HIV therapy.","volume":"3","author":"Astuti","year":"2014","journal-title":"Infect Dis Ther"},{"key":"R4-26-20210309","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/CRD.0b013e3180cabbe7","article-title":"Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens.","volume":"15","author":"Frishman","year":"2007","journal-title":"Cardiol Rev"},{"key":"R5-26-20210309","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2036.2006.02809.x","article-title":"Systematic review: adherence issues in the treatment of ulcerative colitis.","volume":"23","author":"Kane","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-26-20210309","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials.","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R8-26-20210309","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/596482","article-title":"Better adherence with once-daily antiretroviral regimens: a meta-analysis.","volume":"48","author":"Parienti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R9-26-20210309","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1258\/ijsa.2011.011292","article-title":"Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, HAART naive, HIV patients.","volume":"23","author":"Buscher","year":"2012","journal-title":"Int J STD AIDS"},{"key":"R10-26-20210309","doi-asserted-by":"crossref","first-page":"e003028","DOI":"10.1136\/bmjopen-2013-003028","article-title":"Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV.","volume":"3","author":"Cohen","year":"2013","journal-title":"BMJ Open"},{"key":"R11-26-20210309","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1310\/hct1202-71","article-title":"Factors associated with complete adherence to HIV combination antiretroviral therapy.","volume":"12","author":"Juday","year":"2011","journal-title":"HIV Clin Trials"},{"key":"R12-26-20210309","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/PPA.S22771","article-title":"Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.","volume":"5","author":"Nachega","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"R13-26-20210309","first-page":"115","article-title":"One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects.","volume":"4","author":"Airoldi","year":"2010","journal-title":"Patient Prefer Adher"},{"key":"R14-26-20210309","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1097\/QAD.0b013e328340a209","article-title":"A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV homeless and marginally housed people.","volume":"24","author":"Bangsberg","year":"2010","journal-title":"AIDS"},{"key":"R17-26-20210309","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.eimc.2012.03.007","article-title":"Executive summary. Consensus document of GESIDA and SPNS (Spanish Secretariat for the National Plan on AIDS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus.","volume":"30","year":"2012","journal-title":"Enferm Infec Microbiol Clin"},{"key":"R18-26-20210309","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.","volume":"312","author":"Gunthard","year":"2014","journal-title":"JAMA"},{"key":"R19-26-20210309","doi-asserted-by":"crossref","first-page":"19034","DOI":"10.7448\/IAS.17.1.19034","article-title":"French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.","volume":"17","author":"Hoen","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"R20-26-20210309","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.7999","article-title":"HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.","volume":"312","author":"Marrazzo","year":"2014","journal-title":"JAMA"},{"key":"R21-26-20210309","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/jac\/dkt533","article-title":"Antiretroviral treatment French guidelines 2013: economics influencing science.","volume":"69","author":"Raffi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R22-26-20210309","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1155\/2011\/169045","article-title":"Antiretroviral therapy for adults infected with HIV: guidelines for health care professionals from the Quebec HIV care committee.","volume":"22","author":"Rouleau","year":"2011","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"R24-26-20210309","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2478\/abm-2010-0066","article-title":"Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010.","volume":"4","author":"Sungkanuparph","year":"2010","journal-title":"Asian Biomed"},{"issue":"Suppl 1","key":"R25-26-20210309","first-page":"1","article-title":"British HIV Association guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012 (updated November 2013).","volume":"15","author":"Williams","year":"2014","journal-title":"HIV Med"},{"key":"R26-26-20210309","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2165\/11203800-000000000-00000","article-title":"Efavirenzemtricitabinetenofovir disoproxil fumarate single-tablet regimen (Atripla): a review of its use in the management of HIV infection.","volume":"70","author":"Deeks","year":"2010","journal-title":"Drugs"},{"key":"R27-26-20210309","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravircobicistatemtricitabinetenofovir disoproxil fumarate versus efavirenzemtricitabinetenofovir disoproxil fumarate for the initial treatment of HIV infection.","volume":"25","author":"Cohen","year":"2011","journal-title":"AIDS"},{"key":"R28-26-20210309","first-page":"89","article-title":"Single-tablet regimens in HIV: does it really make a difference Curr Med Res O","volume":"30","author":"Aldir","year":"2014","journal-title":"pin"},{"key":"R29-26-20210309","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2147\/CEOR.S48246","article-title":"Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines.","volume":"5","author":"Colombo","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"R30-26-20210309","first-page":"9","article-title":"Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.","volume":"10","author":"Colombo","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"R31-26-20210309","doi-asserted-by":"crossref","first-page":"e47376","DOI":"10.1371\/journal.pone.0047376","article-title":"Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.","volume":"7","author":"Beck","year":"2012","journal-title":"PLoS ONE"},{"key":"R32-26-20210309","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R35-26-20210309","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R36-26-20210309","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R37-26-20210309","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/hiv.12097","article-title":"Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start.","volume":"15","author":"Angeletti","year":"2014","journal-title":"HIV Med"},{"key":"R38-26-20210309","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.","volume":"14","author":"Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R39-26-20210309","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirineemtricitabinetenofovir disoproxil fumarate vs. efavirenzemtricitabinetenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.","volume":"28","author":"Cohen","year":"2014","journal-title":"AIDS"},{"key":"R40-26-20210309","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/CEOR.S38977","article-title":"Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen.","volume":"5","author":"Colombo","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"R41-26-20210309","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","article-title":"Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.","volume":"51","author":"Dejesus","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R42-26-20210309","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QAI.0000000000000199","article-title":"Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen.","volume":"66","author":"Engsig","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R43-26-20210309","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2334-14-26","article-title":"Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naive or switching for simplification HIV-infected patients.","volume":"14","author":"Fabbiani","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R44-26-20210309","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1080\/09540121.2013.766305","article-title":"Using cost as a consideration for antiretroviral regimen selection: an example using average wholesale prices.","volume":"25","author":"Grimes","year":"2013","journal-title":"AIDS Care"},{"key":"R45-26-20210309","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/QAI.0000000000000082","article-title":"Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women.","volume":"65","author":"Hanna","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R46-26-20210309","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/09540121.2013.844766","article-title":"Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1pillday versus any other pill burden.","volume":"26","author":"Hill","year":"2014","journal-title":"AIDS Care"},{"key":"R47-26-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2191-1991-2-16","article-title":"Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs.","volume":"2","author":"Homar","year":"2012","journal-title":"Health Econ Rev"},{"key":"R48-26-20210309","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/09540121.2010.543884","article-title":"A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.","volume":"23","author":"Juday","year":"2011","journal-title":"AIDS Care"},{"key":"R49-26-20210309","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3851\/IMP2675","article-title":"Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA trial.","volume":"19","author":"Landman","year":"2014","journal-title":"Antivir Ther"},{"key":"R52-26-20210309","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0000000000000087","article-title":"Simplification to rilpivirineemtricitabinetenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.","volume":"28","author":"Palella","year":"2014","journal-title":"AIDS"},{"key":"R53-26-20210309","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1473-3099(14)70796-0","article-title":"Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.","volume":"14","author":"Pozniak","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R54-26-20210309","first-page":"196","article-title":"Effectiveness and safety of generic fixed-dose combination of tenofoviremtricitabineefavirenz in HIV-1-infected patients in western India.","volume":"10","author":"Pujari","year":"2008","journal-title":"MedGenMed"},{"key":"R55-26-20210309","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/QAI.0b013e318286415c","article-title":"A randomized, double-blind comparison of coformulated elvitegravircobicistatemtricitabinetenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results,.","volume":"62","author":"Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R56-26-20210309","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"R57-26-20210309","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R58-26-20210309","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/QAD.0b013e328353b047","article-title":"Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals.","volume":"26","author":"Scourfield","year":"2012","journal-title":"AIDS"},{"key":"R59-26-20210309","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.hivar.2014.05.001","article-title":"Adherence to single-tablet versus multiple-tablet regimens in the treatment of HIV infection: a questionnaire-based survey on patients satisfaction.","volume":"13","author":"Skwara","year":"2014","journal-title":"HIV AIDS Rev"},{"key":"R60-26-20210309","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/PPA.S31385","article-title":"Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era.","volume":"6","author":"Sterrantino","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"R61-26-20210309","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-158-2-201301150-00002","article-title":"Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.","volume":"158","author":"Walensky","year":"2013","journal-title":"Ann Intern Med"},{"key":"R62-26-20210309","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"R63-26-20210309","doi-asserted-by":"crossref","first-page":"18060","DOI":"10.7448\/IAS.15.6.18060","article-title":"Association of partial adherence (PA) to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population Abstract.","volume":"15","author":"Cohen","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"R64-26-20210309","first-page":"935","article-title":"Do fixed-dose combination pills or unit-of-use packaging improve adherence A systematic review.","volume":"82","author":"Connor","year":"2004","journal-title":"Bull World Health Organ"},{"key":"R65-26-20210309","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1258\/0956462021925117","article-title":"Factors associated with adherence to antiretroviral medication in HIV-infected patients.","volume":"13","author":"Molassiotis","year":"2002","journal-title":"Int J STD AIDS"},{"issue":"Suppl 1","key":"R66-26-20210309","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1097\/01.qai.0000243112.91293.26","article-title":"The elusive gold standard. Future perspectives for HIV adherence assessment and intervention.","volume":"43","author":"Chesney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R67-26-20210309","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy.","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"R69-26-20210309","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1742-6405-7-12","article-title":"Recent key advances in human immunodeficiency virus medicine and implications for China.","volume":"7","author":"Sun","year":"2010","journal-title":"AIDS Res Ther"},{"issue":"Suppl 3","key":"R70-26-20210309","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3851\/IMP2898","article-title":"Simplification of antiretroviral therapy: a necessary step in the public health response to HIVAIDS in resource-limited settings.","volume":"19","author":"Vitoria","year":"2014","journal-title":"Antivir Ther"},{"key":"R71-26-20210309","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review.","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R72-26-20210309","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.2174\/1381612820666140620162629","article-title":"Statin treatment non-adherence and discontinuation: clinical implications and potential solutions.","volume":"20","author":"Phan","year":"2014","journal-title":"Curr Pharm Des"},{"key":"R73-26-20210309","doi-asserted-by":"crossref","first-page":"948","DOI":"10.5414\/CP202132","article-title":"Association between non-adherence to statin and hospitalization for cardiovascular disease and all-cause mortality in a national cohort.","volume":"52","author":"Shin","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R74-26-20210309","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia.","volume":"8","author":"Morken","year":"2008","journal-title":"BMC Psychiatry"},{"key":"R76-26-20210309","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2052-3211-7-9","article-title":"Healthcare reform in the United States and China: pharmaceutical market implications.","volume":"7","author":"Daemmrich","year":"2014","journal-title":"J Pharm Policy Pract"},{"key":"R77-26-20210309","first-page":"1","article-title":"The impact of health technology assessments: an international comparison.","volume":"12","author":"Kanavos","year":"2010","journal-title":"Euro Observer"},{"key":"R78-26-20210309","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1517\/14656566.2012.729040","article-title":"Treatment of HIV infection with once-daily regimens.","volume":"13","author":"Permpalung","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R80-26-20210309","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1874120701004010041","article-title":"Patent pooling for promoting access to antiretroviral drugs (ARVs)a strategic option for India.","volume":"4","author":"Satyanarayana","year":"2010","journal-title":"Open AIDS J"},{"key":"R84-26-20210309","doi-asserted-by":"crossref","first-page":"e25310","DOI":"10.1371\/journal.pone.0025310","article-title":"Economic returns to investment in AIDS treatment in low and middle income countries.","volume":"6","author":"Resch","year":"2011","journal-title":"PLoS ONE"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T23:49:52Z","timestamp":1718149792000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201510030-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":68,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001677","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}